Compare Albertsons Companies Inc (ACI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albertsons Companies Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Albertsons Companies Inc trades at $14.27 (market cap $6.93B), while Ginkgo Bioworks Holdings Inc trades at $8.78 (market cap $610.13M). The key difference: Albertsons Companies Inc is far larger — about 11.4× Ginkgo Bioworks Holdings Inc's market cap, and Albertsons Companies Inc pays a 4.81% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| ACI | DNA | |
|---|---|---|
Market Cap | $6.93B | $610.13M |
Sector | Consumer Staples | Health |
52-Week High | $22.33 | $16.14 |
52-Week Low | $13.45 | $5.48 |
Enterprise Value | $22.02B | $647.37M |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $14.14, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong earnings momentum with three consecutive quarterly beats, though profitability margins remain thin at 0.26% net income margin. Analyst consensus is bullish with a $18.75 price target representing 33% upside potential. Recent developments include AI-powered search enhancements and retail media partnerships driving innovation.
ACI presents a compelling value opportunity with attractive valuation metrics (P/S: 0.09, EV/EBITDA: 6.49) and consistent revenue growth, though investors face risks from declining profit margins, increasing debt levels, and competitive grocery market pressures. The technical picture remains bearish despite fundamental strengths.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
